比美珠单抗治疗中重度斑块性银屑病。

Q1 Medicine

Skin therapy letter Pub Date : 2021-05-01

Ryan D Gotesman, Ron Vender

{"title":"比美珠单抗治疗中重度斑块性银屑病。","authors":"Ryan D Gotesman, Ron Vender","doi":"","DOIUrl":null,"url":null,"abstract":"Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"26 3","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bimekizumab for Moderate-to-Severe Plaque Psoriasis.\",\"authors\":\"Ryan D Gotesman, Ron Vender\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.\",\"PeriodicalId\":21829,\"journal\":{\"name\":\"Skin therapy letter\",\"volume\":\"26 3\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin therapy letter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

牛皮癣是一种免疫介导的炎症性皮肤病，影响约2%的人口，并与许多合并症有关。最近的研究表明，白细胞介素-17信号在银屑病的发病机制中起着至关重要的作用。Bimekizumab是一种新型单克隆抗体治疗银屑病，使用单一结合位点抑制IL-17A和IL-17F。在这里，我们将讨论比美珠单抗治疗中重度斑块型银屑病的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Bimekizumab for Moderate-to-Severe Plaque Psoriasis.

Psoriasis is an immune-mediated inflammatory skin disease that affects about 2% of the population and is associated with many comorbidities. Recent advances have demonstrated interleukin (IL)-17 signaling plays a crucial role in the pathogenesis of psoriasis. Bimekizumab is a novel monoclonal antibody treatment for psoriasis that uses a single binding site to inhibit IL-17A and IL-17F. Here we will discuss the safety and efficacy of bimekizumab in the treatment of moderate-to-severe plaque psoriasis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skin therapy letter Medicine-Medicine (all)

CiteScore

2.80

自引率

0.00%

发文量

期刊介绍： The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.